Medicaments and proteins based on TGF-β monomers for the treatment of wounds
First Claim
Patent Images
1. A method of accelerating wound healing, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a monomeric wild-type TGF-β
- 3 or a biologically active fragment thereof to accelerate healing of a wound.
1 Assignment
0 Petitions
Accused Products
Abstract
There is provided the use of monomeric TGF-βs, or there fragments or derivatives, as medicaments. These medicaments preferably comprise monomeric TGF-β3, or fragments or derivatives thereof. The medicaments provided may be used in the acceleration of wounding and/or the inhibition of scarring, in the promotion of epithelial regeneration, or in the prevention and/or treatment of fibrotic disorders.
-
Citations
37 Claims
-
1. A method of accelerating wound healing, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a monomeric wild-type TGF-β
- 3 or a biologically active fragment thereof to accelerate healing of a wound.
- View Dependent Claims (2, 3, 4, 5, 6, 19, 20, 27, 28, 29, 30, 31)
-
7. A method for promoting epithelial regeneration while inhibiting scarring, the method comprising administering to a patient in need thereof a therapeutically effective amount of a monomeric wild-type TGF-β
- 3 or a biologically active fragment thereof to promote epithelial regeneration and inhibit scarring.
- View Dependent Claims (8, 9, 16, 21, 22)
-
10. A method of inhibiting scarring, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a monomeric wild-type TGF-β
- 3 or a biologically active fragment thereof to inhibit scarring.
- View Dependent Claims (11, 12, 13, 14, 15, 23, 24)
-
17. A method of accelerating wound healing while inhibiting scarring, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a monomeric wild-type TGF-β
- or a biologically active fragment thereof to accelerate wound healing and inhibit scarring.
- View Dependent Claims (18, 25, 26)
-
32. A method of accelerating wound healing, the method comprising administering by injection to a patient in need thereof 50-200 ng of monomeric wild-type TGF-β
- 3 /linear cm of wound immediately prior to the forming of a wound to accelerate healing of the wound.
-
33. A method for promoting epithelial regeneration while inhibiting scarring, the method comprising administering by injection to a patient in need thereof 50-200 ng of monomeric wild-type TGF-β
- 3/cm2 of epithelial damage immediately prior to the forming of a wound to the patient to promote epithelial regeneration and inhibit scarring.
-
34. A method of inhibiting scarring, the method comprising administering by injection to a patient in need thereof 50-200 ng of monomeric wild-type TGF-β
- 3/cm2 of epithelial damage immediately prior to the forming of a wound to the patient to inhibit scarring.
-
35. A method of accelerating wound healing, the method comprising administering by injection to a patient in need thereof (a) immediately prior to formation of a wound and (b) again 24 hours after wounding, a therapeutically effective amount of monomeric wild-type TGF-β
- 3 to accelerate healing of the wound.
-
36. A method for promoting epithelial regeneration while inhibiting scarring, the method comprising administering by injection to a patient in need thereof (a) immediately prior to formation of a wound and (b) again 24 hours after wounding, a therapeutically effective amount of monomeric wild-type TGF-β
- 3 to promote epithelial regeneration and inhibit scarring.
-
37. A method of inhibiting scarring, the method comprising administering by injection to a patient in need thereof (a) immediately prior to formation of a wound and (b) again 24 hours after wounding, a therapeutically effective amount of monomeric wild-type TGF-β
- 3 to inhibit scarring.
Specification